iDose TR shows sustained IOP reduction at 36 months in new analysis
Click Here to Manage Email Alerts
Key takeaways:
- In a separate study, iDose TR with cataract surgery reduced IOP by a mean of 11.3 mm Hg at 6 months.
- Glaukos has started a phase 2b/3 clinical program for iDose TREX.
Patients with glaucoma treated with iDose TR experienced sustained IOP reductions, according to a press release from Glaukos.
The company announced the positive data along with other clinical updates for the iDose platform.
In a 36-month follow-up analysis from two phase 3 pivotal clinical trials, 70% of patients who underwent treatment with the iDose TR (travoprost intracameral implant) remained well controlled on the same or fewer IOP-lowering topical medications compared with 58% of patients in the control group who received timolol. The implant also demonstrated tolerability and a favorable safety profile.
In a phase 4 study of 60 patients with open-angle glaucoma, the iDose TR implanted in combination with cataract surgery helped achieve a mean IOP reduction of 11.3 mm Hg at 6 months compared with baseline, according to the release.
Glaukos also announced that it is starting a phase 2b/3 clinical program for iDose TREX, a next-generation therapy that has almost twice as much drug capacity as iDose TR.
“We continue to believe there is an important unmet clinical need and strong appetite within the ophthalmic community for safe, effective and sustained procedural pharmaceutical alternatives to traditional topical medications,” Glaukos chairman and CEO Thomas Burns said in the release. “These clinical updates leave us ideally positioned to advance our mission to transform vision therapies for the benefit of patients around the globe suffering from chronic eye diseases.”
Read more about
Click Here to Manage Email Alerts